# A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

> **NCT05662319** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 91 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **DRUG:** Fitusiran
- **DRUG:** Clotting factor concentrates (CFC) or bypassing agents (BPA)
- **DRUG:** Antithrombin concentrate (ATIIIC)

## Key facts

- **NCT ID:** NCT05662319
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2027-03-25
- **Final completion:** 2029-01-25
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662319, "A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05662319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*